NCT00873457View on ClinicalTrials.gov

Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

April 30, 2013

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

perifosine

Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
collaborator

Keryx Biopharmaceuticals

INDUSTRY

collaborator

Keryx / AOI Pharmaceuticals, Inc.

INDUSTRY

lead

Daphne Friedman

OTHER